Temasek’s ClavystBio, Lightstone Ventures back Allay...

added blog Sức khỏe

2025-06-09 05:04:15 -

Temasek’s ClavystBio, Lightstone Ventures back Allay Therapeutics’ $57.5M Series D financing

Allay Therapeutics, a clinical-stage biotechnology company, announced last Thursday the completion of a $57.5 million Series D financing round with leading global investors. The firm said in a statement that Lightstone Ventures and Temasek-backed ClavystBio co-led the Series D financing with participation by existing investors NEA, Arboretum Ventures, Vertex Growth, Vertex Ventures Healthcare,...

0 Bình luận 0 Chia sẻ 462 Lượt xem 0 Đánh giá